SCHEMBL2378818

SCHEMBL2378818

N#CN(C(=N)N)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
IDO1 P14902 4/20 0.36
HTR3E A5X5Y0 2/20 0.36
HTR3B O95264 2/20 0.36
HTR3A P46098 2/20 0.36
HTR3D Q70Z44 2/20 0.36
HTR3C Q8WXA8 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 2/20 0.33
GAA P10253 1/20 0.33
MAPK1 P28482 1/20 0.33
GFER P55789 1/20 0.33
CHIA Q9BZP6 1/20 0.33
SLC22A2 O15244 1/20 0.32
SLC22A1 O15245 1/20 0.32
SLC22A3 O75751 1/20 0.32
PLAU P00749 1/20 0.32
CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8854244 0.90 KMT2A (0.31) IDO1MAPTKMT2ATDP1MAPK1
SCHEMBL4259665 0.80 KMT2A (0.40) LMNAIDO1HTR3EHTR3BHTR3A
SCHEMBL11173933 0.73 GAA (0.43) LMNAALDH1A1MAPTKMT2ATDP1
SCHEMBL16679452 0.73 MAPT (0.41) ALDH1A1MAPTKMT2ATDP1GAA
SCHEMBL3392509 0.73 LMNA (0.48) LMNAIDO1HTR3EHTR3BHTR3A
SCHEMBL27717908 0.71 LMNA (0.46) LMNAIDO1HTR3EHTR3BHTR3A
SCHEMBL11635936 0.71 LMNA (0.46) LMNAIDO1HTR3EHTR3BHTR3A
SCHEMBL2418864 0.70 ALDH1A1 (0.36) LMNAIDO1HTR3EHTR3BHTR3A
SCHEMBL14058840 0.68 LMNA (0.43) LMNAIDO1HTR3EHTR3BHTR3A
SCHEMBL28527559 0.68 ALDH1A1 (0.42) LMNAIDO1HTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111979114-A Black cattle epidemic prevention inspection kit and preparation method thereof 潍坊友容实业有限公司 2020-11-24 CN claimed
CN-114173560-B Articles comprising crosslinked guanidine-containing polymers and uses thereof 舒万诺知识产权公司 2024-07-09 CN disclosed
US-20240024205-A1 DENTAL RETRACTION COMPOSITION SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2024-01-25 US disclosed
US-11827864-B2 Wipe with a guanidinyl-containing polymer 3M INNOVATIVE PROPERTIES COMPANY (US) 2023-11-28 US disclosed
US-11766386-B2 Medical composition containing guanidinyl-containing polymer(s) and carrageenane(s) 3M INNOVATIVE PROPERTIES COMPANY (US) 2023-09-26 US disclosed
US-20230100885-A1 WIPE WITH A GUANIDINYL-CONTAINING POLYMER SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2023-03-30 US disclosed
US-11576845-B2 Methods of removing spores comprising alcohol, acrylate copolymer particles, and a cationic coated article 3M INNOVATIVE PROPERTIES COMPANY (US) 2023-02-14 US disclosed
US-11572341-B2 Biguanide compound and use thereof IMMUNOMET THERAPEUTICS INC. (US) 2023-02-07 US disclosed
US-20220241458-A1 Removable Film-Forming Gel Compositions Featuring Adhesion Promoters KINDEVA DRUG DELIVERY L.P. (US) 2022-08-04 US disclosed
CN-114173560-A Article comprising crosslinked guanidino-containing polymers and uses thereof 3M创新有限公司 2022-03-11 CN disclosed
US-20160115430-A1 WIPE WITH A GUANIDINYL-CONTAINING POLYMER SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2016-04-28 US disclosed
EP-2889625-A1 LIGAND GUANIDINYL FUNCTIONALIZED POLYMERS 3M Innovative Properties Company (US) 2015-07-01 EP disclosed
EP-2542889-B1 LIGAND GUANIDINYL FUNCTIONALIZED POLYMERS 3M INNOVATIVE PROPERTIES CO (US) 2015-03-25 EP disclosed
US-20130224825-A1 LIGAND FUNCTIONALIZED POLYMERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-08-29 US disclosed
US-20130217032-A1 LIGAND FUNCTIONALIZED POLYMERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-08-22 US disclosed
US-8435776-B2 Ligand functionalized polymers 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-05-07 US disclosed
US-20110263901-A1 Process of Preparation of Proguanil USV LTD. (IN) 2011-10-27 US disclosed
US-20110217752-A1 LIGAND FUNCTIONALIZED POLYMERS 3M INNOVATIVE PROPERTIES COMPANY 2011-09-08 US disclosed
EP-2150528-A2 PROCESS FOR PREPARATION OF PROGUANIL HYDROCHLORIDE USV Limited (IN) 2010-02-10 EP disclosed
WO-2009113092-A2 PROCESS FOR PREPARATION OF PROGUANIL HYDROCHLORIDE USV LIMITED (IN) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024205-A1 DENTAL RETRACTION COMPOSITION GK, GANC, JMJD1C LMNA 1790/4885IDO1 4592/4885HTR3E 4426/4885
US-11766386-B2 Medical composition containing guanidinyl-containing polymer(s) and carrageenane(s) GANC, GMPS, MGAM LMNA 3606/4885IDO1 4515/4885HTR3E 2723/4885
US-11576845-B2 Methods of removing spores comprising alcohol, acrylate copolymer particles, and a cationic coated article ACR, CUTA, PRKDC LMNA 1262/4885IDO1 3924/4885HTR3E 1559/4885
US-11572341-B2 Biguanide compound and use thereof MKI67, GCG, GCKR LMNA 3013/4885IDO1 2577/4885HTR3E 3330/4885
US-20110263901-A1 Process of Preparation of Proguanil GCG, PREP, G6PD LMNA 80/4885IDO1 806/4885HTR3E 1857/4885
US-11827864-B2 Wipe with a guanidinyl-containing polymer GNPDA1, GDA, PGLS LMNA 3599/4885IDO1 1324/4885HTR3E 3112/4885
US-20130224825-A1 LIGAND FUNCTIONALIZED POLYMERS SELPLG, CD69, SIGLEC7 LMNA 3067/4885IDO1 2843/4885HTR3E 1411/4885
US-20110217752-A1 LIGAND FUNCTIONALIZED POLYMERS SELPLG, CD69, SIGLEC7 LMNA 3067/4885IDO1 2843/4885HTR3E 1411/4885
US-20230100885-A1 WIPE WITH A GUANIDINYL-CONTAINING POLYMER GNPDA1, GDA, PGLS LMNA 3599/4885IDO1 1324/4885HTR3E 3112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.